Blueprint Medicines Corp (BPMC) USD0.001
Blueprint Medicines Corporation is a precision therapy company focused on genomically defined cancers and hematologic disorders. The Company is focused on crafting drug candidates that provide clinical responses to patients without adequate treatment options. Its lead medicines are AYVAKIT/AYVAKYT (avapritinib) and GAVRETO (pralsetinib). Avapritinib is used for the treatment of systemic mastocytosis (SM), a rare hematologic disorder that causes an overproduction of mast cells and the accumulation of mast cells in the bone marrow and other organs. It is also commercializing avapritinib for the treatment of patients with PDGFRA exon 18 mutant gastrointestinal stromal tumors (GIST). The Company is developing and commercializing pralsetinib for the treatment of RET fusion-positive non-small cell lung cancer (NSCLC), and for the treatment of RET-altered thyroid carcinoma, including medullary thyroid carcinoma (MTC).
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.